Vascular Health and Risk Management Dovepress an Update on the Treatment of Type 1 and Type 2 Diabetes Mellitus: Focus on Insulin Detemir, a Long-acting Human Insulin Analog

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Early insulin treatment in type 2 diabetes

  2013cited by this paper
• A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs

  2010cited by this paper
• Comparing Insulins Detemir and Glargine in Type 2 Diabetes: More Similarities than Differences

  2010cited by this paper
• Euglycemic Infusion of Insulin Detemir Compared With Human Insulin Appears to Increase Direct Current Brain Potential Response and Reduces Food Intake While Inducing Similar Systemic Effects

  2010cited by this paper
• Comparison of insulin detemir and insulin glargine using a basal‐bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

  2009cited by this paper
• Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

  2009cited by this paper
• Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.

  2009cited by this paper
• Insulin analogs and pregnancy: an update

  2009cited by this paper
• Three-year efficacy of complex insulin regimens in type 2 diabetes.

  2009cited by this paper
• Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

  2009cited by this paper
• Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.

  2009cited by this paper
• The Diabetes Control and Complications Trial: the gift that keeps giving

  2009cited by this paper
• No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

  2009cited by this paper
• Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin

  2009cited by this paper
• Mitogenic potency of insulin glargine.

  2009cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.

  2008cited by this paper
• Reduced Weight Gain with Insulin Detemir Compared to NPH Insulin Is Not Explained by a Reduction in Hypoglycemia

  2008cited by this paper
• A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

  2008cited by this paper
• Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study

  2008cited by this paper
• Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine

  2008cited by this paper
• A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Treatment DOI: 10.1111/j.1464-5491.2008.02407.x

  2007cited by this paper
• Does insulin detemir have a role in reducing risk of insulin‐associated weight gain?

  2007cited by this paper
• Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes

  2007cited by this paper
• Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index

  2007cited by this paper
• Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

  2007cited by this paper
• Refining basal insulin therapy: what have we learned in the age of analogues?

  2007cited by this paper
• A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

  2007cited by this paper
• Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

  2007cited by this paper
• Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes

  2007cited by this paper
• Cerebrocortical Beta Activity in Overweight Humans Responds to Insulin Detemir

  2007cited by this paper
• Time‐action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups *

  2006cited by this paper
• Novel insulin analogues and its mitogenic potential

  2006cited by this paper
• Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.

  2006cited by this paper
• A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

  2005cited by this paper
• Insulin detemir used in basal‐bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

  2005cited by this paper
• Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

  2005cited by this paper
• The 12-Month Efficacy and Safety of Insulin Detemir and NPH Insulin in Basal-Bolus Therapy for the Treatment of Type 1 Diabetes

  2004cited by this paper
• Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes

  2004cited by this paper
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

  2004cited by this paper
• Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

  2004cited by this paper
• Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

  2003cited by this paper
• Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.

  2003cited by this paper
• New insulins in the treatment of diabetes mellitus.

  2002cited by this paper
• Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

  2001cited by this paper
• Insulin therapy in type 2 diabetes.

  2001cited by this paper
• Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

  2000cited by this paper
• Variation and trends in incidence of childhood diabetes in Europe

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.

  1999cited by this paper
• Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.

  1998cited by this paper
• Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus.

  1997cited by this paper
• Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs

  1996cited by this paper

• Experience with insulin detemir for type 2 diabetes in older people and people with comorbidities.

  2025cites this paper
• Management strategies for patients with insulin allergy at risk of acute complications: experience from a case report

  2025cites this paper
• Unraveling the Intricate Roles of Exosomes in Cardiovascular Diseases: A Comprehensive Review of Physiological Significance and Pathological Implications

  2023cites this paper
• Exosomes: current knowledge and future perspectives

  2023cites this paper
• Comparison of Insulin Glargine and Detemir Effects on Hormones of Appetite and Metabolic Control in Patients with Type 1 Diabetes: A Randomized Clinical Trial

  2021cites this paper
• Exosomes in Cardiovascular Diseases: Pathological Potential of Nano-Messenger

  2021cites this paper
• Long-acting insulin management for blood glucose prediction models.

  2019cites this paper
• Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature

  2018cites this paper
• Redefining Lifestyle to Improve Metabolic Health

  2018cites this paper
• NOVEL THERAPEUTIC APPROACHES TOWARDS TYPE 1 DIABETES MELLITUS

  2018cites this paper
• Development of the endocrine pancreas and novel strategies for β-cell mass restoration and diabetes therapy

  2015cites this paper
• Insulin Detemir Does Not Cross the Human Placenta

  2015cites this paper
• Bioavailability of insulin detemir and human insulin at the level of peripheral interstitial fluid in humans, assessed by open‐flow microperfusion

  2015cites this paper
• Understanding Type 1 Diabetes and Its Treatment – Some Remaining Difficulties

  2015cites this paper
• Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells.

  2014cites this paper
• Genetically modified pig models for human diseases.

  2013cites this paper
• Differentiation of Stem Cells into Insulin-Producing Cells: Current Status and Challenges

  2013cites this paper
• Ist ein neues Arzneimittel sein Geld wert? Wessen Geld? – Bewertung eines neuen Diabetes-Präparats mit Hilfe eines Discrete-Choice-Experiments

  2013cites this paper
• Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients

  2013cites this paper
• Insulin Detemir

  2012cites this paper
• Effect of Fortified Bread with turmeric and Some Plant Seeds on Diabetic Rats

  2012cites this paper
• Clinical impact of serum proteins on drug delivery.

  2012cites this paper
• Insulin therapy

  2011cites this paper
• Genetic modifications of pigs for medicine and agriculture

  2011cites this paper
• Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.

  2011cites this paper
• The hypoglycaemic effect of pumpkins as anti-diabetic and functional medicines

  2011cites this paper
• Cost–effectiveness of insulin detemir: a systematic review

  2011cites this paper
• Acute Modulation of Endothelial Cell Glucose Transport: A Dissertation

  2010cites this paper
• Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog

  2010cites this paper
• Clinical Pharmacology: Advances and Applications Dovepress Detemir as a Once-daily Basal Insulin in Type 2 Diabetes

  year unknowncites this paper